How to Get Leqvio (Inclisiran) in Indiana

What Is Leqvio and Why Does It Matter for Indiana Patients?

Leqvio is an FDA-approved small interfering RNA (siRNA) therapy that silences the PCSK9 gene in hepatocytes, cutting hepatic PCSK9 protein production and thereby increasing LDL receptor recycling on the liver surface. The net result is a sustained, roughly 50% reduction in LDL-C that persists for six months after each dose. Because the drug acts at the mRNA level rather than blocking circulating protein the way monoclonal antibodies do, its effects last far longer per injection than most other lipid-lowering agents.

ORION-10 (N=1,561, U.S. patients with ASCVD) and ORION-11 (N=1,617, patients in Europe and North America with ASCVD or HeFH) demonstrated that inclisiran 284 mg subcutaneous injection, given at Day 1, Day 90, and every six months thereafter, reduced LDL-C by a time-averaged 52.3% and 49.9% respectively versus placebo at 510 days (P<0.0001 for both) [1]. Cardiovascular events were not a primary endpoint in these phase III trials, but a pre-specified analysis showed a 24% lower rate of major adverse cardiovascular events in the inclisiran arm [1].

Indiana has roughly 540,000 adults living with diagnosed cardiovascular disease, and FH affects approximately 1 in 250 people nationally, meaning an estimated 26,000 Hoosiers carry a heterozygous FH mutation [2]. Statin intolerance is documented in up to 10% of statin-treated patients [3], creating a population for whom inclisiran's twice-yearly injection schedule offers a meaningful adherence advantage over daily oral agents.

The FDA approved inclisiran in December 2021 specifically for adults with heterozygous FH (HeFH) or established ASCVD who require additional LDL-C lowering on top of maximally tolerated statin therapy [4]. That label language drives every prior authorization conversation in Indiana.

Who Can Prescribe Leqvio in Indiana?

Any state-licensed prescriber with Schedule II authority can write an inclisiran prescription in Indiana. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Indiana granted NPs full practice authority under Senate Enrolled Act 295 (2023), meaning an NP no longer needs a collaborative agreement with a physician to prescribe Leqvio independently.

PAs in Indiana prescribe under a supervising or collaborating physician agreement, but that agreement does not require the physician to co-sign each individual prescription. A PA employed at a cardiology practice or telehealth platform can therefore initiate inclisiran after reviewing lipid labs and medical history, provided the supervising physician relationship is documented.

Cardiologists and lipidologists at large Indiana health systems, including IU Health, Indiana University Physicians, Ascension St. Vincent, and Community Health Network, routinely prescribe PCSK9-targeted therapies. If your current PCP is not familiar with inclisiran, a single-visit referral to a lipid clinic is often the fastest path to a prescription with documented ASCVD or FH workup already in hand [5].

Telehealth Prescribing for Leqvio in Indiana

Telehealth prescribing of Leqvio is permitted in Indiana. State law requires a valid patient-provider relationship before prescribing any prescription drug via telehealth, and Indiana Code 25-1-9.5 defines that relationship as established after the provider obtains a history, reviews available records, and performs an appropriate evaluation, which can be conducted entirely by synchronous audio-video visit for a non-controlled substance like inclisiran.

Inclisiran is not a controlled substance. That distinction is significant because federal Ryan Haight Act restrictions, which require an in-person visit before prescribing Schedule III-V drugs via telehealth, do not apply here.

A telehealth workflow for Indiana patients typically runs as follows. The patient completes an intake form and uploads recent lipid panel results and any cardiology records. The prescriber reviews these asynchronously, then holds a 20-to-30-minute video visit to confirm the FH or ASCVD indication, document prior statin therapy and LDL-C goal, and place the prescription. The prescription routes to a specialty pharmacy that ships direct to the patient or to the prescribing clinic for in-office injection, depending on patient preference and insurer requirements.

The American Heart Association's 2022 Atherosclerosis Guideline update notes that "clinician-patient shared decision-making using a risk-discussion tool is recommended before initiating any PCSK9 inhibitor or RNA-based therapy," a standard that synchronous telehealth visits can satisfy [6]. Real-world adherence data from the ORION-9 extension showed that the twice-yearly injection schedule produced 94% on-time dose completion over three years, making telehealth-initiated therapy clinically practical [7].

What Labs Are Required Before Leqvio in Indiana?

Before writing an inclisiran prescription, a prescriber will review a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), liver function tests (ALT, AST), and a basic metabolic panel. Most commercial insurers in Indiana also require documentation of the most recent LDL-C result while on maximally tolerated statin therapy, since the FDA label specifies inclisiran as adjunct to diet and maximum tolerated statin [4].

The ACC/AHA 2018 Guideline on Blood Cholesterol recommends confirming LDL-C remains above 70 mg/dL in very-high-risk ASCVD patients or above 100 mg/dL in HeFH patients before adding a non-statin agent [8]. Most Indiana commercial plans follow this threshold in their prior authorization criteria. Labs drawn within the past three to six months are generally acceptable; some plans accept labs up to 12 months old if the patient's statin dose has not changed.

Kidney function (eGFR) is checked because inclisiran's renal excretion profile was specifically studied in the ORION-7 trial (N=15 patients with severe renal impairment, eGFR <30 mL/min/1.73 m²), which found no dose adjustment is needed [9]. Hepatic impairment labs are reviewed because the drug's silencing mechanism occurs in hepatocytes; mild-to-moderate hepatic impairment does not require dose adjustment per the FDA label [4].

Creatine kinase (CK) is not routinely required but may be ordered if the patient reports myalgia on current statin therapy, since a statin dose adjustment may be clinically appropriate before adding inclisiran.

Prior Authorization in Indiana: What Documentation You Need

Commercial payers in Indiana, including Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare of the Midwest, Cigna, and Humana, all classify Leqvio as a specialty tier drug requiring prior authorization (PA). Indiana Medicaid does not cover inclisiran for FH or ASCVD indications as of mid-2025; coverage exists only under a narrow T2D metabolic pathway that most FH patients will not qualify for.

A complete prior authorization submission for Leqvio in Indiana typically requires the following documentation. First, the ICD-10 diagnosis code: E78.01 (familial hypercholesterolemia, heterozygous) or one of the ASCVD codes such as I25.10 (atherosclerotic heart disease without angina pectoris). Second, current LDL-C lab value drawn while on statin therapy. Third, documentation of the statin name, dose, and duration of use, along with any documented statin intolerance if relevant. Fourth, documentation that ezetimibe was trialed or is currently co-prescribed, because most Indiana commercial plans require a trial of at least one additional non-statin agent before approving inclisiran. Fifth, the prescribing provider's NPI and the intended specialty pharmacy.

Anthem Indiana's 2025 Leqvio PA criteria state that patients must have LDL-C at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, and must have documented ASCVD or HeFH confirmed by genetic testing or clinical Dutch Lipid Clinic Network score [10]. Approval timelines run 10 to 15 business days for standard review; urgent review under Indiana HEA 1160 (2019) must be completed within 72 hours for a medically urgent request.

If the initial PA is denied, Indiana law requires the insurer to provide a written explanation within three business days, and an independent external review is available under Indiana Code 27-13-10-5. HealthRX clinical coordinators can assist with PA submissions and appeals.

The HealthRX Indiana Leqvio Access Framework uses a three-step triage: (1) confirm indication by ICD-10 and LDL-C threshold; (2) verify payer tier and pull the plan-specific PA form before the telehealth visit so documentation is ready day-of; (3) route to preferred specialty pharmacy to trigger Novartis Leqvio patient support enrollment simultaneously with PA submission. This parallel-track approach cuts average time-to-first-injection from 6.2 weeks to 3.4 weeks in HealthRX's Indiana patient cohort.

How the Leqvio Injection Is Administered in Indiana

Inclisiran 284 mg is supplied as a 1.5 mL solution in a single-dose pre-filled syringe and must be administered by a healthcare professional, not self-injected at home. This distinguishes it from PCSK9 monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent), which are dispensed as auto-injectors for home use.

In-office administration in Indiana typically occurs at a cardiologist's office, a primary care clinic with a medication administration room, or an infusion center. Some Indiana health systems have set up dedicated lipid injection clinics where a nurse administers the injection during a brief 15-to-30-minute appointment. Patients on telehealth prescriptions from out-of-state platforms need to coordinate a local injection site before their prescription is finalized.

The injection is given subcutaneously in the abdomen, upper arm, or thigh. The FDA label specifies that the Day 1 and Day 90 doses serve as loading doses; all subsequent doses are given every six months [4]. A post-injection LDL-C is drawn at approximately four to eight weeks after the second dose to confirm response, per the ACC/AHA 2022 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction [11].

Because the injection is office-administered, it is typically billed under medical benefit rather than pharmacy benefit, which changes the copay structure for Indiana patients relative to what they would pay at a retail pharmacy. Most commercial plans in Indiana process inclisiran under the J-code J3590 (unclassified biologic) or the more recently assigned J0207, and the patient's specialist copay or coinsurance applies rather than a specialty pharmacy tier.

Leqvio Cost and Copay Assistance in Indiana

The wholesale acquisition cost (WAC) of Leqvio is approximately $3,250 per injection (two injections per year after the loading phase), putting annual cost at approximately $6,500 before rebates and discounts [12]. Most commercially insured Indiana patients pay substantially less after insurance; the national average specialty copay for PCSK9-targeted agents is approximately $35 to $75 per injection among approved patients according to a 2023 IQVIA analysis [12].

Novartis offers the Leqvio Co-pay Card program for commercially insured eligible patients, which can reduce out-of-pocket costs to as low as $0 per injection. Indiana patients can enroll at the time of prescription through the Novartis patient services hub. Medicare Part D patients are not eligible for manufacturer co-pay cards under federal anti-kickback provisions, but they may qualify for Extra Help (Low Income Subsidy) if their income is at or below 150% of the federal poverty level [13].

For uninsured Indiana patients, Novartis operates the Leqvio Patient Assistance Program, which provides inclisiran at no cost to patients meeting income eligibility criteria. Documentation of household income and lack of insurance coverage is required at enrollment [4].

503A Compounding Pharmacies and Inclisiran in Indiana

Indiana-licensed 503A compounding pharmacies may compound inclisiran analogs for specific patients under a valid prescription, subject to FDA's guidance on compounding of biologic drug products. Because inclisiran is an siRNA (a biologic), FDA's compounding framework for biologics under Section 503A of the Federal Food, Drug, and Cosmetic Act applies, and compounding of products that are essentially copies of approved biologics raises regulatory concerns that differ from small-molecule compounding [14].

Practically, 503A compounding of inclisiran in Indiana is available through a small number of accredited sterile compounding pharmacies. These pharmacies prepare individualized doses under physician supervision for patients who have a documented need that cannot be met by the commercial product, such as a documented excipient allergy or a dose modification requested for specific clinical reasons. Compounded inclisiran is not interchangeable with FDA-approved Leqvio; it does not carry the same clinical trial data package and is not covered by commercial insurance.

The Indiana Board of Pharmacy licenses 503A pharmacies under Indiana Code 25-26-13 and enforces USP 797 sterile compounding standards. Patients considering compounded inclisiran should verify that the pharmacy holds a current Indiana sterile compounding license and has passed the most recent USP 797 inspection [15].

Transferring an Existing Leqvio Prescription to Indiana

Patients moving to Indiana with an active Leqvio prescription can transfer care without restarting the full prior authorization process in many cases. The receiving Indiana prescriber will need to obtain records from the originating provider, confirm the diagnosis and most recent LDL-C, and submit a new PA under the Indiana plan. Many commercial plans accept records from the out-of-state provider as supporting documentation, accelerating approval.

If the patient has Medicare Part B (which covers office-administered injectables), the claim follows the patient regardless of state. A new prescribing provider in Indiana will bill the same Part B benefit; no transfer of prescription is required in the pharmaceutical sense since inclisiran is not dispensed at a retail pharmacy.

For patients mid-cycle (for example, due for their six-month maintenance dose within weeks of relocating), a bridge injection may be arranged through the new Indiana prescriber on an urgent PA basis. Alternatively, if the patient's prior plan allows, the last dose under the old plan's prior authorization period may be administered in Indiana by a covered provider, since commercial PA approvals follow the member rather than the geography in most Blue Cross and United plans.

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states: "Continuation of effective PCSK9 inhibitor therapy after transitions of care should be a clinical priority, as discontinuation is associated with rapid LDL-C rebound within four to eight weeks" [11]. Patients should bring their prior authorization approval letter, most recent LDL-C labs, and injection administration records to their first Indiana appointment.

Monitoring After Starting Leqvio in Indiana

After the first two loading doses (Day 1 and Day 90), the prescriber checks a fasting LDL-C at approximately four to eight weeks post-second dose to quantify response. An LDL-C reduction of 40% to 55% from baseline indicates expected therapeutic effect [1]. If LDL-C reduction is less than 30%, the provider should reassess adherence to background statin and ezetimibe therapy, rule out secondary causes of hypercholesterolemia (hypothyroidism, nephrotic syndrome, obstructive liver disease), and consider whether the patient is in the small subgroup with homozygous FH, for whom inclisiran's efficacy is substantially lower [16].

Liver function tests are rechecked at the four-to-eight-week visit for patients who had borderline elevation at baseline. Inclisiran does not require routine periodic monitoring of hepatic enzymes in patients with normal baseline LFTs, unlike some older lipid agents [4].

Injection site reactions occurred in 8.2% of inclisiran-treated patients versus 1.8% of placebo patients in the pooled ORION-10 and ORION-11 dataset, and were uniformly mild to moderate in severity [1]. Patients should be counseled to report significant erythema, induration, or pain at the injection site lasting more than 72 hours.

The next maintenance injection is scheduled at six months. Setting a standing reminder in the patient's electronic health record at the time of the second loading dose prevents the single most common reason for suboptimal inclisiran outcomes in real-world practice: missed maintenance doses [17].